HK1068807A1 - Expression vectors encoding epitopes of antigens and methods for their design - Google Patents

Expression vectors encoding epitopes of antigens and methods for their design

Info

Publication number
HK1068807A1
HK1068807A1 HK05101449A HK05101449A HK1068807A1 HK 1068807 A1 HK1068807 A1 HK 1068807A1 HK 05101449 A HK05101449 A HK 05101449A HK 05101449 A HK05101449 A HK 05101449A HK 1068807 A1 HK1068807 A1 HK 1068807A1
Authority
HK
Hong Kong
Prior art keywords
epitope
substrate polypeptide
methods
proteasome
liberation
Prior art date
Application number
HK05101449A
Other languages
English (en)
Inventor
John J L Simard
David C Diamond
Zhiyong Qui
Xiang-Dong Lei
Original Assignee
Mannkind Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27662934&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1068807(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mannkind Corp filed Critical Mannkind Corp
Publication of HK1068807A1 publication Critical patent/HK1068807A1/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/464488—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Spectroscopy & Molecular Physics (AREA)
HK05101449A 2001-11-07 2005-02-22 Expression vectors encoding epitopes of antigens and methods for their design HK1068807A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33696801P 2001-11-07 2001-11-07
PCT/US2002/036098 WO2003063770A2 (fr) 2001-11-07 2002-11-07 Epitopes codant pour des vecteurs d'expression d'antigenes associes a des cibles et procedes permettant leur conception

Publications (1)

Publication Number Publication Date
HK1068807A1 true HK1068807A1 (en) 2005-05-06

Family

ID=27662934

Family Applications (2)

Application Number Title Priority Date Filing Date
HK05101449A HK1068807A1 (en) 2001-11-07 2005-02-22 Expression vectors encoding epitopes of antigens and methods for their design
HK05109682A HK1075473A1 (en) 2001-11-07 2005-10-31 Expression vectors encoding epitopes of target-associated antigens and methods for their design

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK05109682A HK1075473A1 (en) 2001-11-07 2005-10-31 Expression vectors encoding epitopes of target-associated antigens and methods for their design

Country Status (12)

Country Link
US (3) US8637305B2 (fr)
EP (2) EP2314712B1 (fr)
CN (2) CN1313617C (fr)
AT (1) ATE494387T1 (fr)
AU (1) AU2008229722B2 (fr)
CA (1) CA2469738A1 (fr)
DE (1) DE60238864D1 (fr)
DK (1) DK1453471T3 (fr)
ES (1) ES2358642T3 (fr)
HK (2) HK1068807A1 (fr)
MX (1) MXPA04005382A (fr)
WO (1) WO2003063770A2 (fr)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
EP1964573B1 (fr) 1999-10-22 2014-11-26 Aventis Pasteur Limited Procédé d'induction et/ou amélioration d'une réponse immune vers des antigènes de tumeurs
US20030215425A1 (en) * 2001-12-07 2003-11-20 Simard John J. L. Epitope synchronization in antigen presenting cells
WO2003008537A2 (fr) * 2001-04-06 2003-01-30 Mannkind Corporation Sequences d'epitope
CN1313617C (zh) * 2001-11-07 2007-05-02 曼康公司 编码靶相关抗原表位的表达载体及其设计方法
DE60318938T2 (de) 2002-03-20 2009-01-22 Mannkind Corp., Valencia Inhalationsgerät
US7178491B2 (en) * 2003-06-05 2007-02-20 Caterpillar Inc Control system and method for engine valve actuator
WO2004112825A2 (fr) 2003-06-17 2004-12-29 Mannkind Corporation Combinaisons d'antigenes associes a des tumeurs dans des compositions pour divers types de cancers
MXPA05013973A (es) * 2003-06-17 2006-03-02 Mannkind Corp Metodos para producir, mejorar y sustentar respuestas inmunes contra epitopes restringidos mhc clase i, para propositos profilacticos o terapeuticos.
US20070014807A1 (en) * 2003-09-03 2007-01-18 Maida Anthony E Iii Multiplex vaccine
AU2005265182B2 (en) * 2004-06-17 2012-06-21 Mannkind Corporation Epitope analogs
US20060008468A1 (en) * 2004-06-17 2006-01-12 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
US20060159689A1 (en) * 2004-06-17 2006-07-20 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
JP2008503494A (ja) * 2004-06-17 2008-02-07 マンカインド コーポレイション 診断方法を治療方法と統合することによる免疫療法の効力改善
EP1786784B1 (fr) 2004-08-20 2010-10-27 MannKind Corporation Catalyse de la synthese de dicetopiperazine
CA2578175C (fr) 2004-08-23 2014-10-14 Mannkind Corporation Sels de dicetopiperazine, sels de dicetomorpholine ou sels de dicetodioxane permettant l'administration de medicaments
AU2005325715B2 (en) * 2004-12-16 2011-10-06 Wake Forest University Health Sciences Use of flagellin in tumor immunotherapy
EP1835932A2 (fr) * 2004-12-29 2007-09-26 Mannkind Corporation Methodes de declenchement, d'accentuation et de maintien de reponses immunitaires contre des epitopes restreints du cmh de classe i a des fins prophylactiques ou therapeutiques
US20060159694A1 (en) * 2004-12-29 2006-07-20 Chih-Sheng Chiang Combinations of tumor-associated antigens in compositions for various types of cancers
WO2006071990A2 (fr) * 2004-12-29 2006-07-06 Mannkind Corporation Methodes de declenchement d'une reponse immunitaire sans implication de cellules cd+4
WO2006071934A2 (fr) 2004-12-29 2006-07-06 Mannkind Corporation Procedes permettant de declencher, maintenir et manipuler des modificateurs de reponse biologique a l'interieur d'organes lympoides
EP2385060A3 (fr) 2005-06-17 2012-02-15 Mannkind Corporation Procédés et communications pour susciter des réponses immunes polyvalentes contre des épitopes dominants et sous-dominants exprimés sur des cellules cancéreuses et le stroma tumoral
EP2371851A3 (fr) * 2005-06-17 2012-08-01 Mannkind Corporation Analogues d'épitopes
WO2006138568A2 (fr) * 2005-06-17 2006-12-28 Mannkind Corporation Immunotherapie multivalente a effet de declenchement et d'amplification, destinee au traitement d'une tumeur cancereuse
US7803404B2 (en) 2005-09-14 2010-09-28 Mannkind Corporation Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces
BRPI0707991B8 (pt) 2006-02-22 2021-05-25 Mannkind Corp métodos de preparação de um medicamento em pó seco com uma propriedade farmacêutica melhorada, dito pó seco e uso de uma quantidade efetiva do pó seco
US8940871B2 (en) 2006-03-20 2015-01-27 The Regents Of The University Of California Engineered anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting
WO2008008541A2 (fr) * 2006-07-14 2008-01-17 Mannkind Corporation Procédés destinés à susciter, améliorer et entretenir les réponses immunitaires contre des épitopes limités au cmh de classe i dans des buts prophylactiques ou thérapeutiques
ES2527412T3 (es) * 2007-02-15 2015-01-23 Mannkind Corporation Método para aumentar la respuesta de los linfocitos T
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
EP2152890A1 (fr) * 2007-05-23 2010-02-17 MannKind Corporation Vecteurs multicistroniques et procédés pour leur conception
JP6126773B2 (ja) 2007-09-04 2017-05-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 癌のターゲッティングおよび検出のための高親和性抗前立腺幹細胞抗原（ｐｓｃａ）抗体
CA2721366C (fr) 2008-04-17 2017-06-06 Elizabeth Ann Vasievich Stimulation de reponse immunitaire par des enantiomeres de lipides cationiques
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
EP2570147B1 (fr) 2008-06-13 2017-10-18 MannKind Corporation Inhalateur de poudre sèche et système d'administration de médicament
US9364619B2 (en) 2008-06-20 2016-06-14 Mannkind Corporation Interactive apparatus and method for real-time profiling of inhalation efforts
TWI614024B (zh) 2008-08-11 2018-02-11 曼凱公司 超快起作用胰島素之用途
RU2011130796A (ru) 2008-12-24 2013-01-27 Онкотерапи Сайенс, Инк. Пептиды c1orf59 и содержащие их вакцины
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
ES2712732T3 (es) 2009-02-17 2019-05-14 Cornell Res Foundation Inc Métodos y kits para el diagnóstico de cáncer y la predicción de valor terapéutico
PL2405963T3 (pl) 2009-03-11 2014-04-30 Mannkind Corp Urządzenie, układ i sposób pomiaru oporu inhalatora
KR20180079458A (ko) 2009-06-12 2018-07-10 맨카인드 코포레이션 한정된 비표면적을 갖는 디케토피페라진 마이크로입자
WO2011008863A2 (fr) * 2009-07-14 2011-01-20 Lucia Irene Gonzalez Peptides stéréoisomères et leurs conjugués polymères pour infection par le vih
US8673847B2 (en) * 2009-10-05 2014-03-18 The Medical College Of Wisconsin, Inc. Peptide based peroxidase inhibitors and methods of using same
US20110274723A1 (en) 2009-10-23 2011-11-10 Mannkind Corporation Cancer immunotherapy and method of treatment
EP2496295A1 (fr) 2009-11-03 2012-09-12 MannKind Corporation Appareil et méthode de simulation d'efforts d'inhalation
EP2506876B1 (fr) 2009-12-02 2016-10-12 Imaginab, Inc. Minobodies j591 et cys-diabodies pour le ciblage de l'antigène membranaire spécifique de la prostate humaine (psma), et procédés d'utilisation
RU2531455C2 (ru) 2010-06-21 2014-10-20 Маннкайнд Корпорейшн Системы и способы доставки сухих порошковых лекарств
CA2812153C (fr) * 2010-09-20 2020-06-30 Biontech Ag Recepteur des cellules t specifiques des antigenes et epitopes des cellules t
CN105667994B (zh) 2011-04-01 2018-04-06 曼金德公司 用于药物药盒的泡罩包装
WO2012174472A1 (fr) 2011-06-17 2012-12-20 Mannkind Corporation Microparticules de dicétopipérazine de capacité élevée
AU2012328885B2 (en) 2011-10-24 2017-08-31 Mannkind Corporation Methods and compositions for treating pain
CN108057154B (zh) 2012-07-12 2021-04-16 曼金德公司 干粉药物输送系统和方法
AU2013317805B2 (en) 2012-09-21 2018-07-26 Pds Biotechnology Corporation Improved vaccine compositions and methods of use
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
EP2968607B1 (fr) * 2013-03-15 2019-07-24 The Trustees Of The University Of Pennsylvania Vaccins anticancéreux et méthodes de traitement les utilisant
CA2906817C (fr) 2013-03-15 2022-01-18 Mannkind Corporation Compositions de dicetopiperazine microcristallines et procedes
US9925144B2 (en) 2013-07-18 2018-03-27 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
JP2016530930A (ja) 2013-08-05 2016-10-06 マンカインド コーポレイション 通気装置及び方法
CN104761644A (zh) * 2014-01-03 2015-07-08 百奇生物科技（苏州）有限公司 大肠杆菌表达的融合蛋白mbp-mart-1及其制备和应用
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
WO2015153969A1 (fr) 2014-04-04 2015-10-08 The Board Of Trustees Of The Leland Stanford Junior University Découverte de ligands pour les récepteurs de cellule t
WO2015199617A1 (fr) * 2014-06-24 2015-12-30 National University Of Singapore Anticorps monoclonal à spécificité du type récepteur des cellules t qui cible des cellules tumorales humaines infectées par le virus d'epstein-barr sur la base de leur expression d'ebna1
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
EP4137158A1 (fr) 2015-08-07 2023-02-22 Imaginab, Inc. Constructions de liaison d'antigène se liant à des molécules cibles
EP3374496A4 (fr) 2015-11-13 2019-07-10 PDS Biotechnology Corporation Lipides en tant que vecteurs synthétiques pour améliorer le traitement et la présentation de l'antigène ex-vivo en thérapie cellulaire dendritique
CA3029813A1 (fr) 2016-06-13 2017-12-21 Torque Therapeutics, Inc. Methodes et procedes pour favoriser la fonction des cellules immunitaires
GB201616365D0 (en) 2016-09-27 2016-11-09 Helsingin Yliopisto Non-genetic modification of enveloped viruses
MX2019003961A (es) * 2016-10-05 2019-08-26 Pds Biotechnology Corp Vacunas novedosas del vph16 con celulas t no restringidas por hla, composiciones y metodos de uso de las mismas.
WO2018147960A1 (fr) 2017-02-08 2018-08-16 Imaginab, Inc. Séquences d'extension pour dianticorps
US11524033B2 (en) 2017-09-05 2022-12-13 Torque Therapeutics, Inc. Therapeutic protein compositions and methods of making and using the same
CN110950949B (zh) * 2018-09-26 2022-04-05 香雪生命科学技术（广东）有限公司 一种识别ssx2抗原的t细胞受体
CN115819555A (zh) * 2021-09-17 2023-03-21 香雪生命科学技术（广东）有限公司 一种识别ssx2的高亲和力tcr
WO2024092031A1 (fr) * 2022-10-25 2024-05-02 Seismic Therapeutic, Inc. Polypeptides fc d'igg variants et leurs utilisations

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US613066A (en) * 1898-10-25 Bottle-stopper
US4439199A (en) * 1980-02-19 1984-03-27 Alza Corporation Method for administering immunopotentiator
US4683199A (en) * 1983-01-31 1987-07-28 Sloan-Kettering Institute For Cancer Research Interleukin-2 dependent cytotoxic T-cell clones
US5168062A (en) * 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
DE3937412A1 (de) 1989-11-10 1991-05-16 Hoechst Ag Synthetische vakzine zur spezifischen induktion zytotoxischer t-lymphozyten
US5196321A (en) * 1986-10-02 1993-03-23 Massachusetts Institute Of Technology Methods for in vitro cleavage of ubiquitin fusion proteins
US5132213A (en) * 1986-10-02 1992-07-21 Massachusetts Institute Of Technology Method for producing proteins and polypeptides using ubiquitin fusions
US5093242A (en) * 1986-10-02 1992-03-03 Massachusetts Institute Of Technology Methods of generating desired amino-terminal residues in proteins
US4937190A (en) * 1987-10-15 1990-06-26 Wisconsin Alumni Research Foundation Translation enhancer
EP0414689B1 (fr) * 1988-02-12 1994-12-07 Commonwealth Scientific And Industrial Research Organisation Vecteurs du virus de la variole des poules
US5804381A (en) 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
JP3423306B2 (ja) * 1989-11-03 2003-07-07 エル． モートン，ドナルド 尿中腫瘍関連抗原、抗原性サブユニットの使用および検出方法
SE466259B (sv) * 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
DE4143467C2 (de) 1991-05-17 1995-02-09 Max Planck Gesellschaft Peptidmotiv und dessen Verwendung
US5451504A (en) 1991-07-29 1995-09-19 Serex, Inc. Method and device for detecting the presence of analyte in a sample
US6037135A (en) * 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
DE4228458A1 (de) * 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
US5405940A (en) * 1992-08-31 1995-04-11 Ludwig Institute For Cancer Research Isolated nonapeptides derived from MAGE genes and uses thereof
DE4238416A1 (de) 1992-11-13 1994-05-19 Max Planck Gesellschaft Bestimmung von Peptidmotiven auf MHC-Molekülen
US5487974A (en) * 1992-12-22 1996-01-30 Ludwig Institute For Cancer-Research Method for detecting complexes containing human leukocyte antigen A2 (HLA-A2) molecules and a tyrosinase drived peptide on abnormal cells
US5530096A (en) * 1992-12-22 1996-06-25 Ludwig Institute For Cancer Research Isolated, tyrosinase derived peptides and uses thereof
US5744316A (en) * 1992-12-22 1998-04-28 Ludwig Institute For Cancer Research Isolated, tyrosinase derived peptides and uses thereof
US5519117A (en) * 1992-12-22 1996-05-21 Ludwig Institute For Cancer Research Isolated, tyrosinase derived peptides and uses thereof
US5558995A (en) * 1993-01-22 1996-09-24 Ludwig Institute For Cancer Research Peptides which are derived from tumor rejection antigen precursor molecule MAGE-1, which complex to MHC molecule HLA-C clone 10, and uses thereof
US5989565A (en) * 1993-01-29 1999-11-23 University Of Pittsburgh Elution and identification of T cell epitopes from viable cells
ATE386800T1 (de) * 1993-03-17 2008-03-15 Us Gov Health & Human Serv Immunogene chimäre umfassend nucleinsäuresequenzen, die signalsequenzpeptide des endoplasmatischen reticulums und mindestens ein anderes peptid codieren, deren verwendung in impfstoffen und zur behandlung von krankheiten
US5648226A (en) * 1993-07-22 1997-07-15 Ludwig Institute For Cancer Research Isolated peptides derived from tumor rejection antigens, and their use
US5679647A (en) * 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5478556A (en) * 1994-02-28 1995-12-26 Elliott; Robert L. Vaccination of cancer patients using tumor-associated antigens mixed with interleukin-2 and granulocyte-macrophage colony stimulating factor
US5585461A (en) * 1994-03-24 1996-12-17 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US5554506A (en) * 1994-03-24 1996-09-10 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US5554724A (en) * 1994-03-24 1996-09-10 University Of Leiden Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof
US5874560A (en) * 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
IT1266740B1 (it) * 1994-07-01 1997-01-14 Maria Paola Landini Materiale proteico ricombinante legante anticorpi contro il citomegalovirus umano, reagenti diagnostici derivati da tale
DE4423392A1 (de) 1994-07-04 1996-01-11 Birsner & Grob Biotech Gmbh Verfahren zur Identifizierung antigener Peptide
FR2722208B1 (fr) * 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
CA2195642A1 (fr) 1994-07-27 1996-02-08 Andreas Suhrbier Vaccins a base de polyepitopes
US5962428A (en) * 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
US5698396A (en) * 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
CA2249390C (fr) 1996-03-19 2007-12-18 University Of Virginia Patent Foundation Peptides reconnus par des lymphocytes cytotoxiques specifiques du melanome restreints par a1, a2 et a3, leurs utilisations
DE69723434T2 (de) 1996-04-26 2004-05-19 Rijksuniversiteit Te Leiden Verfahren zur selektion und produktion von t-zell-peptide epitope und vakzine mit diese epitope
US5876972A (en) 1996-09-23 1999-03-02 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Nucleic acid molecules coding for tumor suppressor proteins and methods for their isolation
US5990091A (en) * 1997-03-12 1999-11-23 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
US6004777A (en) * 1997-03-12 1999-12-21 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
US6287569B1 (en) * 1997-04-10 2001-09-11 The Regents Of The University Of California Vaccines with enhanced intracellular processing
ES2265165T3 (es) 1997-07-10 2007-02-01 Mannkind Corporation Dispositivo para inducir una respuesta ltc.
US7084239B1 (en) * 1997-10-08 2006-08-01 The United States Of America As Represented By The Department Of Health And Human Services Cancer peptides of NY-ESO-1/CAG-3
EP1030927A1 (fr) * 1997-11-12 2000-08-30 Valentis Inc. Plasmides d'expression utilises dans des vaccins a base d'acide nucleique a plusieurs epitopes
US20030138808A1 (en) 1998-02-19 2003-07-24 Simard John J.L. Expression vectors encoding epitopes of target-associated antigens
CA2323632A1 (fr) 1998-03-13 1999-09-16 Epimmune Inc. Peptides de liaison de hla et leurs applications
US6495136B1 (en) * 1998-03-26 2002-12-17 The Procter & Gamble Company Proteases having modified amino acid sequences conjugated to addition moieties
GB9808932D0 (en) 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
IL125608A0 (en) 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
US6800730B1 (en) * 1998-10-02 2004-10-05 Ludwig Institute For Cancer Research Isolated peptides which bind to MHC class II molecules, and uses thereof
CA2350911A1 (fr) 1998-11-16 2000-05-25 Board Of Regents, The University Of Texas System Induction de lymphocytes t specifiques du vih
AU2720600A (en) 1999-01-08 2000-07-24 Powderject Vaccines, Inc. Vaccination method for efficient induction of cytotoxic t lymphocyte response
AU3162500A (en) 1999-03-03 2000-09-21 Evotec Analytical Systems Gmbh Homogeneous fluorescence assay
DE19909503A1 (de) 1999-03-04 2000-09-07 Boehringer Ingelheim Int Tumorassoziiertes Antigen
DE19919225A1 (de) 1999-04-28 2000-11-16 Boehringer Ingelheim Int Tumorassoziiertes Antigen
JP2003500037A (ja) 1999-05-26 2003-01-07 オレゴン ヘルス アンド サイエンス ユニバーシティー エピトープタンパク質のタグをもつ転移因子
DE19924199A1 (de) 1999-05-27 2000-11-30 Boehringer Ingelheim Int Tumorassoziiertes Antigen
FR2794370B1 (fr) 1999-06-03 2003-10-17 Biovector Therapeutics Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
DE19936563A1 (de) 1999-08-04 2001-02-08 Boehringer Ingelheim Int Tumorassoziiertes Antigen
WO2001018035A2 (fr) 1999-09-08 2001-03-15 Transgene S.A. Peptides derives de muc-1
DE60042556D1 (de) 1999-09-16 2011-02-10 Eisai Inc Für polyepitop-polypeptide kodierende nukleinsäuren
WO2001023577A2 (fr) 1999-09-30 2001-04-05 Institut Pasteur Polynucleotides hybrides ou chimeriques, proteines et compositions comprenant des sequences du virus de l'hepatite b
EP1118860A1 (fr) 2000-01-21 2001-07-25 Rijksuniversiteit te Leiden Méthodes pour sélectionner et produire des épitopes peptidiques de cellules T ainsi que des vaccines comprenant lesdits épitopes sélectionnés
EP1252309A2 (fr) 2000-01-28 2002-10-30 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services Nouveaux epitopes des lymphocytes t restreints de la classe ii du complexe majeur d'histocompatibilite derives de l'antigene du cancer, ny eso-1
US6756044B1 (en) 2000-02-09 2004-06-29 Genvec, Inc. Antigenic complexes and methods
WO2001062917A1 (fr) * 2000-02-22 2001-08-30 Ludwig Institute For Cancer Research Sequences genomiques isolees codant pour le cancer ny-eso-1/antigene de la tumeur des testicules et leurs utilisations
US20030215425A1 (en) * 2001-12-07 2003-11-20 Simard John J. L. Epitope synchronization in antigen presenting cells
NZ521715A (en) 2000-04-28 2008-01-31 Mannkind Corp Method of identifying and producing antigen peptides and use thereof as vaccines
DE10025521A1 (de) 2000-05-23 2001-12-06 Boehringer Ingelheim Int Tumor-assoziiertes Antigen B132
AUPQ776100A0 (en) 2000-05-26 2000-06-15 Australian National University, The Synthetic molecules and uses therefor
CU23235A1 (es) 2001-02-28 2007-09-26 Ct Ingenieria Genetica Biotech POXVIRUS RECOMBINANTES PARA PROTEINAS QUIMéRICAS DEL VIRUS DE LA INMUNODEFICIENCIA HUMANA Y SU APLICACION EN LA TERAPéUTICA Y LA PREVENCION DEL SIDA
WO2003008537A2 (fr) * 2001-04-06 2003-01-30 Mannkind Corporation Sequences d'epitope
GB0118532D0 (en) 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
CN1313617C (zh) * 2001-11-07 2007-05-02 曼康公司 编码靶相关抗原表位的表达载体及其设计方法
JP4179585B2 (ja) 2002-03-29 2008-11-12 ユニ・チャーム株式会社 印刷が施された生分解性プラスチックフィルム
JP2005537800A (ja) 2002-09-06 2005-12-15 マンカインド コーポレイション エピトープ配列

Also Published As

Publication number Publication date
US20030228634A1 (en) 2003-12-11
CN1612935A (zh) 2005-05-04
HK1075473A1 (en) 2005-12-16
DE60238864D1 (de) 2011-02-17
WO2003063770A9 (fr) 2004-06-17
EP2314712B1 (fr) 2014-01-08
WO2003063770A3 (fr) 2004-04-01
CA2469738A1 (fr) 2003-08-07
EP2314712A1 (fr) 2011-04-27
ATE494387T1 (de) 2011-01-15
US8252916B2 (en) 2012-08-28
CN1313617C (zh) 2007-05-02
EP1453471A4 (fr) 2006-11-29
AU2008229722A1 (en) 2008-10-30
ES2358642T3 (es) 2011-05-12
AU2008229722B2 (en) 2012-09-06
MXPA04005382A (es) 2005-02-24
US7232682B2 (en) 2007-06-19
DK1453471T3 (da) 2011-03-28
US20040132088A1 (en) 2004-07-08
EP1453471A2 (fr) 2004-09-08
US8637305B2 (en) 2014-01-28
WO2003063770A2 (fr) 2003-08-07
EP1453471B1 (fr) 2011-01-05
US20040203051A1 (en) 2004-10-14
CN101024842A (zh) 2007-08-29

Similar Documents

Publication Publication Date Title
HK1068807A1 (en) Expression vectors encoding epitopes of antigens and methods for their design
Awaki et al. ASCA observation of three bright early-type galaxies: NGC 4472, NGC 4406, and NGC 4636
EP0677533A3 (fr) Anticorps contre des épitopes homologues aus auto-antigènes, méthode de préparation et applications
ES2094113T3 (es) Dna que codifica cd40.
ATE493186T1 (de) Zelltrennungszusammensetzungen und -verfahren
ATE411515T1 (de) Apparat zur durchführung von leckversuchen an verschlossen verpackungen
EA200600390A1 (ru) Химерные антигены для нарушения толерантности хозяина к чужеродным антигенам
WO2004042795A3 (fr) Procede de preparation de semi-conducteur complet pour analyse
DE69733352D1 (de) Hla-a2.1 bindende peptide und deren verwendung
NZ330475A (en) Antibodies, and use thereof in measuring lipid peroxidation in biological samples and method for inducing inflammation
NO932320L (no) Fremgangsmaate for paavisning av en analytt i en proeve og et utstyrsett for denne
Park et al. High‐resolution mapping of strain partitioning and relaxation in InGaN/GaN nanowire heterostructures
Hillen et al. Contribution of mass spectrometry-based proteomics to immunology
Candreva et al. Identification of cross‐reactive B‐cell epitopes between Bos d 9.0101 (Bos Taurus) and Gly m 5.0101 (Glycine max) by epitope mapping MALDI‐TOF MS
GB9719017D0 (en) An automated procedure for the identification of tubercle bacilli from clinical specimens
Tang et al. Direct Observation of Atomic Structures and Chemical States of Active and Inactive Dopant Sites in Mg-Doped GaN
EP0331514A3 (fr) Essai de la délétion ou du défaut de la protéine de la dystrophie musculaire de Duchenne
AU4277996A (en) Presentation of hydrophobic antigens to t-cells by cd1 molecules
DE69940774D1 (de) Hla-bindende peptide und ihre verwendungen
EP1556404A4 (fr) Antigene p30 genetiquement modifie, combinaison d'antigenes amelioree et utilisations associees
WO1999047102A3 (fr) Methodes pour une presentation amelioree de l'antigene sur des cellules presentatrices de l'antigene, et compositions produites selon ces methodes
EP0316764A3 (en) Detection of tumor-associated markers in biological fluids
Budde et al. Detection of volatile organic contaminants in semiconductor technology- a comparison of investigations by gas chromatography and by ion mobility
EP0190049A3 (en) Method for selecting hybridomas producing antibodies specific to inaccessible cell surface antigens
Stock et al. Studies of deformation in niobium by X-ray topographic methods

Legal Events

Date Code Title Description
CHPA Change of a particular in the register (except of change of ownership)
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20161107